punicalagin and Enterovirus-Infections

punicalagin has been researched along with Enterovirus-Infections* in 2 studies

Other Studies

2 other study(ies) available for punicalagin and Enterovirus-Infections

ArticleYear
Small molecules targeting coxsackievirus A16 capsid inactivate viral particles and prevent viral binding.
    Emerging microbes & infections, 2018, Sep-26, Volume: 7, Issue:1

    Coxsackievirus A16 (CVA16) is an etiologic agent of hand, foot, and mouth disease (HFMD) that affects young children, and although typically self-limited, severe complications, and fatal cases have been reported. Due to the lack of specific medication and vaccines against CVA16, there is currently a need to develop effective antivirals to better control CVA16 infections in epidemic areas. In this study, we identified the tannins chebulagic acid (CHLA) and punicalagin (PUG) as small molecules that can efficiently disrupt the CVA16 infection of human rhabdomyosarcoma cells. Both compounds significantly reduced CVA16 infectivity at micromolar concentrations without apparent cytotoxicity. A mechanistic analysis revealed that the tannins particularly targeted the CVA16 entry phase by inactivating cell-free viral particles and inhibiting viral binding. Further examination by molecular docking analysis pinpointed the targets of the tannins in the fivefold axis canyon region of the CVA16 capsid near the pocket entrance that functions in cell surface receptor binding. We suggest that CHLA and PUG are efficient antagonists of CVA16 entry and could be of value as antiviral candidates or as starting points for developing molecules to treat CVA16 infections.

    Topics: Antiviral Agents; Benzopyrans; Capsid Proteins; Enterovirus A, Human; Enterovirus Infections; Glucosides; Humans; Hydrolyzable Tannins; Molecular Docking Simulation; Small Molecule Libraries; Tannins; Virus Attachment

2018
Antiviral activity of punicalagin toward human enterovirus 71 in vitro and in vivo.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2012, Dec-15, Volume: 20, Issue:1

    Human enterovirus 71 is one of the major causative agents of hand, foot and mouth disease in children and has caused mortalities in large-scale outbreaks in the Asia-Pacific region in recent years. No vaccine or antiviral therapy is available currently in the clinic. In this work, we investigated the antiviral effect of punicalagin on enterovirus 71 both in vitro and in vivo. The results showed that punicalagin reduced the viral cytopathic effect on rhabdomyosarcoma cells with an IC₅₀) value of 15 μg/ml. Moreover, punicalagin treatment of mice challenged with a lethal dose of enterovirus 71 resulted in a reduction of mortality and relieved clinical symptoms by inhibiting viral replication. Our work suggested that punicalagin have the potential for further development as antiviral agents against enterovirus 71.

    Topics: Animals; Antiviral Agents; Cell Line, Tumor; Cytopathogenic Effect, Viral; Enterovirus A, Human; Enterovirus Infections; Foot-and-Mouth Disease; Humans; Hydrolyzable Tannins; Lythraceae; Mice; Mice, Inbred ICR; Phytotherapy; Plant Extracts; Virus Replication

2012